The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Eli Lilly's revenues will grow 1.1% and EPS will expand 14.1%.
The average estimate for revenue is $5.66 billion. On the bottom line, the average EPS estimate is $1.05.
Last quarter, Eli Lilly notched revenue of $5.96 billion. GAAP reported sales were 1.5% lower than the prior-year quarter's $6.05 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.85. GAAP EPS of $0.74 for Q4 were 3.9% lower than the prior-year quarter's $0.77 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 79.0%, 90 basis points better than the prior-year quarter. Operating margin was 21.3%, 90 basis points better than the prior-year quarter. Net margin was 13.9%, 30 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $22.95 billion. The average EPS estimate is $3.90.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,243 members out of 1,343 rating the stock outperform, and 100 members rating it underperform. Among 433 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 412 give Eli Lilly a green thumbs-up, and 21 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Eli Lilly is hold, with an average price target of $51.97.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Eli Lilly. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Eli Lilly to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Better Buy: GlaxoSmithKline plc vs. Eli Lilly
Both big pharma stocks have growth drivers. But both also come with baggage.
Is Eli Lilly and Company a Buy in 2018?
The outlook is complicated for this big pharma stock.
Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.